Clinical Trial Update: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of GSK1572932A as adjuvant therapy in non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GSK1572932A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 3 | Status: TERMINATED | Results posted: 2019-01-30